New Cancer Research

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message:

Sent on Thursday, 2007 Sep 13.

Search benign prostate hyperplasia
Click on the following url to view complete results in pubmed. (Results may change over time.)
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0Q2mm1HjEg5nttstNXVmj5fX7NjNOX7olbq5CilxAuRpgSDoLe66AoPcjq95zfN&WebCubbyUser=00cSZEVcn6hWuNV5jVIoSSog%401FC0550A6E9DAE00_0042SID
To unsubscribe from these e-mail updates click on the following url
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0Ox6CKPK-FhuL74RrvpMz1CKCnW0ZXvXZRnWRwotZBb2PcrdZ&WebCubbyUser=00cSZEVcn6hWuNV5jVIoSSog%401FC0550A6E9DAE00_0042SID

==================== Entrez pubmed Results ======================

Item 1 of 1

1: Br J Cancer. 2007 May 7;96(9):1475-9. Epub 2007 May 1.

Benign prostatic hyperplasia and subsequent risk of bladder cancer.

Kang D, Chokkalingam AP, Gridley G, Nyren O, Johansson JE, Adami HO, Silverman
D, Hsing AW.

Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda, Maryland 20892-7234, USA.

We evaluated the risk of bladder cancer in a cohort of 79,280 Swedish men
hospitalised for benign prostatic hyperplasia (BPH), identified in the Swedish
Inpatient Register between 1964 and 1983 and followed until 1989 via multiple
record linkages with nationwide data on cancer registry, death and emigration.
Standardised incidence ratios (SIRs), the ratios of the observed to the expected
numbers of incident bladder cancers, were used to calculate the risk associated
with BPH. The expected number was calculated by multiplying the number of
person-years by the age-specific cancer incidence rates in Sweden for each
5-year age group and calendar year of observation. Analyses were stratified by
BPH treatment, latency, calendar year and presence of genitourinary (GU)
comorbid conditions. After excluding the first 3 years of follow-up after the
index hospitalisation, we observed 506 incident bladder cancer cases during
follow-up in the cohort. No overall increased risk of bladder cancer was
apparent in our main analysis involving the entire BPH cohort. However, among
BPH patients with transurethral resection of the prostate (TURP), there was an
increased risk in all follow-up periods; SIRs of bladder cancer during years 4-6
of follow-up was 1.22 (95% confidence interval=1.02-1.46), 1.32 for 7-9 years of
follow-up, and 1.47 for 10-26 years of follow-up. SIRs of bladder cancer among
TURP-treated BPH patients were particularly elevated among those with comorbid
conditions of the GU tract (e.g., stone, infection, etc.); 1.72, 1.74 and 2.01
for 4-6, 7-9, 10-26 years of follow-up, respectively, and also for those whose
diagnoses occurred before 1975, when TURP was more likely to be performed by a
urologist than a general practitioner: 1.87, 1.90 and 1.74, respectively. These
findings suggest that BPH overall is not associated with bladder cancer risk.
However, among men treated with TURP, particularly those with other comorbid GU
tract conditions, risk of bladder cancer was elevated.

Publication Types:
Research Support, N.I.H., Intramural

PMID: 17473820 [PubMed - indexed for MEDLINE]